

**HYALOSE SCIENTISTS TO PRESENT AT THE 7th INTERNATIONAL
CONFERENCE ON HYALURONAN IN CHARLESTON, S.C. IN APRIL, 2007**

Oklahoma City, OK and Austin, TX—April 2, 2007— Emergent Technologies Inc. (ETI) of Austin announced today that four Hyalose, L.L.C. scientists will be presenting at the 7th International Conference on Hyaluronan to be held at the Francis Marion Hotel in Charleston, S.C. the week of April 22-27, 2007. The quadrennial conference is presented by the International Society of Hyaluronan Sciences (ISHAS) (www.ishas.org) and hosted by the Department of Cell Biology at the Medical University of South Carolina.

Dr. Paul Weigel, Hyalose Chief Scientist, is presenting in the first session on Perspectives and New Horizons. The title of his talk is, “Hyaluronan Synthases (HAS): Ancient Molecular and Cellular Intimacy, Current Puzzles, Future Wisdom.”

Dr. Paul DeAngelis, Hyalose Chief Scientist, is presenting in the second session on Structure, Synthesis and Degradation. The title of his talk is, “Analysis and Use of Hyaluronan Synthases.”

Dr. Michael Haller, Hyalose Research Scientist and Head of Chemical Development, and Dr. Wei Jing, Hyalose Research Scientist and Project Manager, are presenting a poster entitled, “Production of Defined Hyaluronan or Modified Hyaluronan Molecules Ranging From Oligomers to Mega-Dalton Polymers.”

Mr. Tommy Harlan, CEO of Hyalose and CEO of ETI, commented, “We are delighted and very proud of our scientists and their contribution to and participation in the conference.” John Hoopingarner, COO of Hyalose and Executive VP of ETI, added, “Our scientists are uniquely positioned and qualified to address not only the intricacies of the basic science of hyaluronan, but also to predict where, how and for what purposes this unique biopolymer may be used in commercial products and applications. They serve our company and the industry well.”

ETI formed Hyalose in its first investment fund, Emergent-OU, Ltd., in 2000, and manages it and its sister companies from its Austin, Texas, headquarters. Hyalose licensed the rights from the University of Oklahoma to technology patented by Drs. Weigel and DeAngelis related to the production of hyaluronic acid (HA) which is a biopolymer used in formulations for high-end Wound Healing, Drug Delivery, Osteoarthritis, Ophthalmology, Cosmetics and Dermatology, Urology, Tissue Engineering, and Anti-Adhesion Surgical Devices applications. Visit its website at www.hyalose.com

Harlan founded ETI in 1989 and launched its first venture capital fund in 1998. ETI specializes in forming, funding, commercializing, and managing biotech companies for the purpose of converting institutional and university-based technology into high-return ventures. Visit its website at www.emergentechnologies.com

Contact: Mr. John Hoopingarner
 2508 Ashley Worth Blvd., Suite 200
 Austin, TX 78738
 (T) 512/697-8205(F) 512/263-3236

KEYWORD: Austin, Oklahoma City

INDUSTRY KEYWORD: MEDICAL DEVICE, COSMETICS, OSTEOARTHRITIS,
OPHTHALMICS, BIOPOLYMER, GLYCOBIOLOGY, UNIVERSITY
OF OKLAHOMA, ISHAS, HYALURONAN, HYALURONIC ACID